-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OjPSyPtjDm8FbdhvE8K/qCZQky2LpBw7bUiAQFX54DtmEi9vVoyf5jqMIATBaE5H Qdm0KtpT7lWIp7PEJdEtGw== 0001421000-10-000005.txt : 20101101 0001421000-10-000005.hdr.sgml : 20101101 20101101120255 ACCESSION NUMBER: 0001421000-10-000005 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20101101 DATE AS OF CHANGE: 20101101 EFFECTIVENESS DATE: 20101101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCION THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001421000 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-149834 FILM NUMBER: 101153997 BUSINESS ADDRESS: STREET 1: 2400 BOSTON STREET, SUITE 330 CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: (410) 522-8701 MAIL ADDRESS: STREET 1: 2400 BOSTON STREET, SUITE 330 CITY: BALTIMORE STATE: MD ZIP: 21224 FORMER COMPANY: FORMER CONFORMED NAME: ARCION THEREAPEUTICS INC DATE OF NAME CHANGE: 20071212 D 1 primary_doc.xml X0704 D LIVE 0001421000 ARCION THERAPEUTICS, INC. 2400 BOSTON STREET, SUITE 330 BALTIMORE MD MARYLAND 21224 (410) 522-8701 DELAWARE ARCION THEREAPEUTICS INC Corporation true 2007 James Campbell c/o Arcion Therapeutics, Inc. 2400 Boston Street, Suite 330 Baltimore MD MARYLAND 21224 Executive Officer Director Kerrie Brady c/o Arcion Therapeutics, Inc. 2400 Boston Street, Suite 330 Baltimore MD MARYLAND 21224 Executive Officer Arnold Oronsky c/o Arcion Therapeutics, Inc. 2400 Boston Street, Suite 330 Baltimore MD MARYLAND 21224 Director Cynthia McCormick c/o Arcion Therapeutics, Inc. 2400 Boston Street, Suite 330 Baltimore MD MARYLAND 21224 Director David Collier c/o Arcion Therapeutics, Inc. 2400 Boston Street, Suite 330 Baltimore MD MARYLAND 21224 Director Biotechnology Decline to Disclose 06 false 2010-10-20 false true true false 0 2000000 400000 1600000 false 3 0 0 0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. false ARCION THERAPEUTICS, INC. /s/ Kerrie Brady Kerrie Brady Chief Operating Officer 2010-10-29 -----END PRIVACY-ENHANCED MESSAGE-----